We are live on
!
Find out more
AG
Artal Group Portfolio holdings
AUM
$931M
1-Year Est. Return
41.63%
This Fund
S&P 500
This Quarter
Est. Return
+29.93%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.38B
AUM Growth
-$1.54B
(-39%)
Cap. Flow
-$2.1B
Cap. Flow
% of AUM
-88.13%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
112
New
–
Increased
–
Reduced
2
Closed
110
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CAVA Group
CAVA
|
+$610M |
| 2 |
Scholar Rock
SRRK
|
+$93.8M |
| 3 |
Kymera Therapeutics
KYMR
|
+$89.7M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$86.1M |
| 5 |
Arrowhead Research
ARWR
|
+$82.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 91.02% |
| 2 | Healthcare | 8.98% |
| 3 | Communication Services | 0% |
| 4 | Real Estate | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Remitly
RELY
$4.62B
| – | – |
-25,000
| Closed | -$303K |
|
77
Regenxbio
RGNX
$525M
| – | – |
-250,000
| Closed | -$2.92M |
|
|
RNAM
78
DELISTED
Avidity Biosciences
RNAM
| – | – |
-655,555
| Closed | -$26.8M |
|
79
Cartesian Therapeutics
RNAC
$239M
| – | – |
-304,554
| Closed | -$8.23M |
|
80
Revolution Medicines
RVMD
$43.9B
| – | – |
-1,015,776
| Closed | -$39.4M |
|
81
Sea Limited
SE
$62.9B
| – | – |
-97,500
| Closed | -$6.96M |
|
82
Seer Inc
SEER
$105M
| – | – |
-4,750,000
| Closed | -$7.98M |
|
83
Sagimet Biosciences
SGMT
$650M
| – | – |
-724,771
| Closed | -$2.48M |
|
84
Solid Biosciences
SLDB
$897M
| – | – |
-2,500,000
| Closed | -$14.2M |
|
|
SLN
85
Silence Therapeutics
SLN
$774M
| – | – |
-2,779,619
| Closed | -$52.8M |
|
|
SLRN
86
DELISTED
ACELYRIN
SLRN
| – | – |
-2,020,888
| Closed | -$8.91M |
|
87
Snowflake
SNOW
$114B
| – | – |
-5,051
| Closed | -$682K |
|
|
88
Scholar Rock
SRRK
$6.09B
| – | – |
-11,259,438
| Closed | -$93.8M |
|
|
SWTX
89
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-1,313,026
| Closed | -$49.5M |
|
90
Tango Therapeutics
TNGX
$4.03B
| – | – |
-2,519,841
| Closed | -$21.6M |
|
|
TRML
91
DELISTED
Tourmaline Bio
TRML
| – | – |
-91,426
| Closed | -$1.18M |
|
92
Taysha Gene Therapies
TSHA
$1.65B
| – | – |
-4,354,214
| Closed | -$9.75M |
|
93
Tesla
TSLA
$1.41T
| – | – |
-2,000
| Closed | -$396K |
|
94
TSMC
TSM
$2.15T
| – | – |
-26,000
| Closed | -$4.52M |
|
95
Visa
V
$701B
| – | – |
-19,000
| Closed | -$4.99M |
|
96
Vera Therapeutics
VERA
$2.43B
| – | – |
-915,974
| Closed | -$33.1M |
|
|
VIGL
97
DELISTED
Vigil Neuroscience
VIGL
| – | – |
-1,828,691
| Closed | -$7.31M |
|
98
Wave Life Sciences
WVE
$879M
| – | – |
-4,566,251
| Closed | -$22.8M |
|
99
Xenon Pharmaceuticals
XENE
$5.45B
| – | – |
-381,554
| Closed | -$14.9M |
|
100
Alto Neuroscience
ANRO
$1.19B
| – | – |
-350,000
| Closed | -$3.74M |
|
Similar funds
BCM
ACM
SAM
NS
PA
ACM
CICI
CAM
Artal Group's Q3 2024 Portfolio in Review
As of Q3 2024, Artal Group held 112 positions worth $2.38B, down 39% from $3.92B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Artal Group withdrew a net $2.1B in Q3 2024, closing 110 positions and reducing 2 holdings. Its most notable exit was Scholar Rock, an estimated $93.8M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 91% of assets, up from 56% a quarter earlier, followed by Healthcare and Communication Services.
- Artal Group's biggest Q3 2024 reduction was CAVA Group, cutting an estimated $610M.
- Artal Group fully exited Scholar Rock in Q3 2024, selling an estimated $93.8M.
- Artal Group's ten largest holdings make up 100% of its $2.38B portfolio in Q3 2024.
- Artal Group opened 0 new positions and closed 110 in Q3 2024.
- Artal Group's portfolio value fell 39% quarter-over-quarter to $2.38B.
Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.